PulseAugur
EN
LIVE 05:15:34

OncoTraj benchmark launched for lung cancer drug resistance prediction

By PulseAugur Editorial · [1 sources] ·

Researchers have introduced OncoTraj, a new public benchmark designed to advance the prediction of drug resistance in non-small cell lung cancer. This benchmark comprises longitudinal data from 813 patients treated with osimertinib, harmonized from multiple clinical-genomic sources. OncoTraj includes three defined tasks for model evaluation: predicting progression at 12 months, estimating time to progression, and classifying resistance mechanisms. Initial results indicate that current models struggle with single-timepoint data, highlighting the need for serial ctDNA analysis in future iterations. AI

IMPACT Establishes a standardized benchmark for AI models in predicting cancer drug resistance, guiding future research towards more effective longitudinal analysis.

RANK_REASON The cluster describes a new benchmark and dataset for a specific medical research problem, published on arXiv. [lever_c_demoted from research: ic=1 ai=1.0]

Read on arXiv cs.LG →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

COVERAGE [1]

  1. arXiv cs.LG TIER_1 English(EN) · Aarchi Singh Thakur ·

    OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib

    Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating computational models on the corresponding longitud…

RELATED TOPICS